FY2027 Earnings Estimate for ACRS Issued By Leerink Partnrs

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at Leerink Partnrs boosted their FY2027 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued to clients and investors on Wednesday, October 15th. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will post earnings per share of ($0.82) for the year, up from their previous forecast of ($0.90). The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Aclaris Therapeutics’ FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($0.93) EPS.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The firm had revenue of $1.78 million during the quarter, compared to analysts’ expectations of $1.34 million. Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.

A number of other equities analysts have also commented on ACRS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclaris Therapeutics in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, June 25th. Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Aclaris Therapeutics in a research note on Monday, June 23rd. Finally, Piper Sandler started coverage on Aclaris Therapeutics in a research note on Thursday, July 10th. They issued an “overweight” rating and a $6.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Aclaris Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $8.71.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $1.90 on Friday. Aclaris Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $5.17. The business has a 50-day moving average of $1.89 and a two-hundred day moving average of $1.57. The stock has a market capitalization of $205.83 million, a P/E ratio of -1.39 and a beta of 0.26.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Millennium Management LLC lifted its stake in shares of Aclaris Therapeutics by 111.0% in the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after purchasing an additional 2,175,101 shares during the period. Decheng Capital LLC increased its position in shares of Aclaris Therapeutics by 78.3% in the 1st quarter. Decheng Capital LLC now owns 4,041,736 shares of the biotechnology company’s stock valued at $6,184,000 after buying an additional 1,775,069 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Aclaris Therapeutics by 108.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after buying an additional 1,282,042 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Aclaris Therapeutics by 25.9% in the 1st quarter. Acadian Asset Management LLC now owns 2,195,191 shares of the biotechnology company’s stock valued at $3,355,000 after buying an additional 451,044 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Aclaris Therapeutics by 71.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 681,553 shares of the biotechnology company’s stock valued at $1,043,000 after buying an additional 284,191 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.